Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Cancer drugs funding

Everolimus is available to patients in Wales after deal agreed with Novartis

Everolimus has been made available to treat patients in Wales with certain types of renal, pancreatic or breast cancers, or non-cancerous brain or kidney tumours associated with tuberous sclerosis complex. In the image, CT scan of a kidney tumour

Source: Simon Fraser / Freeman Hospital, Newcastle Upon Tyne / Science Photo Library

Wales has reached an agreement with Novartis on everolimus being available to treat patients with certain types of cancer and tumours. In the image, CT scan of a kidney tumour

Everolimus has been made available to treat patients in Wales with certain types of renal, pancreatic or breast cancers, or non-cancerous brain or kidney tumours associated with tuberous sclerosis complex.

The arrangement — the first of its kind and announced on 10 November 2015 — is a two-year agreement reached between the Welsh government and Novartis.

Everolimus will be available where “the clinician, in discussion with the patient, believes it is the appropriate treatment”, a spokesperson for the Welsh government says. She confirmed that an individual patient funding request (IPFR) would not be required for the treatment, which can cost £36,000 per year.

In contrast, for patients living in England, clinicians must make an IPFR to receive funding for the treatment from NHS England. This will only be successful if the patient meets NHS England’s definition of being exceptional.

As part of the deal, Novartis will establish an observational study in Wales to assess outcomes for patients with breast cancer treated with everolimus and exemestane. The company will also offer financial support to various healthcare initiatives in Wales that aim to increase healthcare professional education and improve patient support for conditions treated by everolimus.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200132

Readers' comments (1)

  • The article refers to to a 'spokesperson for the Welsh government says. She confirmed that an that an individual patient funding request (IPFR) would not be required for the treatment....'

    Can you confirm the name of the Welsh government spokesperson?

    Regards Hugh Prosser

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Everolimus has been made available to treat patients in Wales with certain types of renal, pancreatic or breast cancers, or non-cancerous brain or kidney tumours associated with tuberous sclerosis complex. In the image, CT scan of a kidney tumour

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.